Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zamtocabtagene autoleucel - Miltenyi Biomedicine

Next Previous
Drug Profile

Zamtocabtagene autoleucel - Miltenyi Biomedicine

Alternative Names: Anti-CD20-anti-CD19 CAR T cells; Anti-CD2019 CAR T cells; CAR-20/19-T cells - Miltenyi Biotec; CD20-CD19-targeting CAR T Cells; CD2019-targeting CAR T cells; MB-CART2019.1; zamto-cel

Latest Information Update: 21 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Miltenyi Biomedicine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-Hodgkin's lymphoma
  • Phase II B-cell lymphoma; Diffuse large B cell lymphoma
  • Phase I/II Multiple sclerosis
  • Clinical Phase Unknown Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 06 May 2026 Miltenyi Biomedicine in collaboration with National Heart, Lung, and Blood Institute and National Cancer Institute plans a phase II FRONTIER trial for Mantle cell lymphoma (Second-line therapy or greater) in September 2026 (IV, Infusion) (NCT07569965)
  • 17 Dec 2025 Miltenyi Biotec GmbH plans a phase II DALY II Japan trial for Diffuse-large-B-cell-lymphoma (Second line therapy or greater) in Japan (IV, Infusion) in December 2025 (NCT07288879) (jRCT2033250384)
  • 11 Dec 2025 Phase-II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in Japan (IV) (NCT07288879)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top